dehydroepiandrosterone has been researched along with Mood Disorders in 14 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this pilot study was to evaluate the effect of dehydroepiandrosterone (DHEA) on depressed mood and fatigue in HIV+ men and women, unselected for baseline DHEA level." | 5.09 | DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. ( Ferrando, SJ; Rabkin, JG; Rabkin, R; Wagner, GJ, 2000) |
| "Patients with affective disorders have reduced levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate; the most pronounced deficiency of neuroprotective neurosteroids is typical of patients with a single depressive episode." | 1.42 | Serum levels of neurosteroids in patients with affective disorders. ( Bokhan, NA; Ivanova, SA; Lebedeva, EV; Levchuk, LA; Simutkin, GG; Vyalova, NM, 2015) |
| "In addition, among the PTSD subjects, the peak change in DHEA in response to ACTH1-24 was negatively correlated with the total Clinician Administered PTSD Scale score, while the peak DHEA to cortisol ratio was inversely associated with negative mood symptoms measured by the Profile of Mood States scale." | 1.32 | An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. ( Charney, DS; Gudmundsen, G; Lipschitz, DS; Morgan, CA; Mustone, ME; Rasmusson, AM; Shi, Q; Vasek, J; Vojvoda, D; Wolfe, J, 2004) |
| "Memory deficits were not explained by mood disturbances." | 1.30 | Pregnancy, the postpartum, and steroid hormones: effects on cognition and mood. ( Bluestein, BW; Buckwalter, DK; Buckwalter, JG; Chang, L; Goodwin, TM; McCleary, CA; Rankin, KP; Stanczyk, FZ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pluchino, N | 1 |
| Drakopoulos, P | 1 |
| Bianchi-Demicheli, F | 1 |
| Wenger, JM | 1 |
| Petignat, P | 1 |
| Genazzani, AR | 1 |
| Levchuk, LA | 1 |
| Vyalova, NM | 1 |
| Ivanova, SA | 1 |
| Simutkin, GG | 1 |
| Lebedeva, EV | 1 |
| Bokhan, NA | 1 |
| Šrámková, M | 1 |
| Dušková, M | 1 |
| Hill, M | 1 |
| Bičíková, M | 1 |
| Řípová, D | 1 |
| Mohr, P | 1 |
| Stárka, L | 1 |
| Roumen, FJ | 1 |
| Zimmerman, Y | 1 |
| van Wijck, A | 1 |
| Ter Kuile, MM | 1 |
| Onghena, P | 1 |
| Coelingh Bennink, HJ | 1 |
| Poretsky, L | 1 |
| Song, L | 1 |
| Brillon, DJ | 1 |
| Ferrando, S | 1 |
| Chiu, J | 1 |
| McElhiney, M | 1 |
| Ferenczi, A | 1 |
| Sison, C | 1 |
| Haller, I | 1 |
| Rabkin, J | 1 |
| Rasmusson, AM | 1 |
| Vasek, J | 1 |
| Lipschitz, DS | 1 |
| Vojvoda, D | 1 |
| Mustone, ME | 1 |
| Shi, Q | 1 |
| Gudmundsen, G | 1 |
| Morgan, CA | 1 |
| Wolfe, J | 1 |
| Charney, DS | 1 |
| Arlt, W | 2 |
| Buckwalter, JG | 1 |
| Stanczyk, FZ | 1 |
| McCleary, CA | 1 |
| Bluestein, BW | 1 |
| Buckwalter, DK | 1 |
| Rankin, KP | 1 |
| Chang, L | 1 |
| Goodwin, TM | 1 |
| Noda, Y | 1 |
| Kamei, H | 1 |
| Nabeshima, T | 1 |
| Hendrick, V | 1 |
| Gitlin, M | 1 |
| Altshuler, L | 1 |
| Korenman, S | 1 |
| Rabkin, JG | 1 |
| Ferrando, SJ | 1 |
| Wagner, GJ | 1 |
| Rabkin, R | 1 |
| Rigaud, AS | 1 |
| Pellerin, J | 1 |
| Rubinow, DR | 1 |
| Hoban, MC | 1 |
| Grover, GN | 1 |
| Galloway, DS | 1 |
| Roy-Byrne, P | 1 |
| Andersen, R | 1 |
| Merriam, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pituitary Gonadotropin Response to GnRH Stimulation in Menstrual, Climacteric and, Menopause-Related Mood and Behavioral Disorders[NCT00001232] | 140 participants | Observational | 1988-07-31 | Completed | |||
| The Treatment of Menstrually-Related Mood Disorders With Continuous Gonadal Steroid Replacement[NCT00005011] | 22 participants (Actual) | Observational | 2000-03-28 | Completed | |||
| The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)[NCT00001259] | Phase 1 | 60 participants (Actual) | Interventional | 1992-08-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.~Each participant completed the BDI every 2 weeks during each of the study phases throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone; weeks 6 and 8 of placebo alone; during the 4-week long estradiol phase (weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (weeks 2 and 4 of progesterone)." (NCT00001259)
Timeframe: Placebo: Weeks 6 and 8 of Placebo; Lupron only: Weeks 6 and 8 or 10 and 12; Estradiol or progesterone: Weeks 2 and 4
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 2.6 |
| GnRH Agonist Injections (Lupron-L Only) | 3.0 |
| Estradiol | 5.3 |
| Progesterone | 3.6 |
6 reviews available for dehydroepiandrosterone and Mood Disorders
| Article | Year |
|---|---|
Neurobiology of DHEA and effects on sexuality, mood and cognition.
Topics: Affect; Animals; Anxiety; Brain; Cognition; Cognition Disorders; Dehydroepiandrosterone; Dehydroepia | 2015 |
Dehydroepiandrosterone replacement therapy.
Topics: Adrenal Insufficiency; Aging; Animals; Autoimmune Diseases; Cognition Disorders; Dehydroepiandroster | 2004 |
Androgen therapy in women.
Topics: Adolescent; Adrenal Glands; Adult; Aged; Androgens; Dehydroepiandrosterone; Female; Hormone Replacem | 2006 |
[Sigma-receptor ligands and anti-stress actions].
Topics: Animals; Dehydroepiandrosterone; Dextromethorphan; Humans; Ligands; Mood Disorders; Neuropeptide Y; | 1999 |
Antidepressant medications, mood and male fertility.
Topics: Androgens; Animals; Antidepressive Agents; Clinical Trials as Topic; Dehydroepiandrosterone; Emotion | 2000 |
[Neuropsychic effects of dehydroepiandrosterone].
Topics: Affect; Aging; Animals; Attention; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandros | 2001 |
3 trials available for dehydroepiandrosterone and Mood Disorders
| Article | Year |
|---|---|
Mood disturbances during combined oral contraceptive use and the effect of androgen supplementation. Results of a double-blind, placebo-controlled, single-case alternation design pilot study.
Topics: Affect; Androstenes; Contraceptives, Oral, Combined; Dehydroepiandrosterone; Double-Blind Method; Dr | 2017 |
Metabolic and hormonal effects of oral DHEA in premenopausal women with HIV infection: a randomized, prospective, placebo-controlled pilot study.
Topics: Administration, Oral; Affect; Androstenedione; Dehydroepiandrosterone; Dihydrotestosterone; Double-B | 2009 |
DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.
Topics: Adult; Affect; Androgens; Body Composition; CD4 Lymphocyte Count; Dehydroepiandrosterone; Dehydroepi | 2000 |
5 other studies available for dehydroepiandrosterone and Mood Disorders
| Article | Year |
|---|---|
Serum levels of neurosteroids in patients with affective disorders.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; Male; Middle Aged; Mood Diso | 2015 |
The role of steroids in the prediction of affective disorders in adult men.
Topics: Adult; Anxiety; Dehydroepiandrosterone; Depression; Female; Gas Chromatography-Mass Spectrometry; Hu | 2017 |
An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD.
Topics: Adrenal Glands; Adult; Aging; Behavior; Cosyntropin; Dehydroepiandrosterone; Dehydroepiandrosterone | 2004 |
Pregnancy, the postpartum, and steroid hormones: effects on cognition and mood.
Topics: Adult; Affect; Awards and Prizes; Cognition; Dehydroepiandrosterone; Estradiol; Female; Humans; Hydr | 1999 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |
Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects.
Topics: Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; Estradiol; Female; Foll | 1988 |